Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus CLOBETASOL PROPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus CLOBETASOL PROPIONATE.
CAPEX vs CLOBETASOL PROPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines and suppression of immune response via modulation of gene expression.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Apply topically as a thin film to affected areas once to twice daily. Maximum 50 g/week. Treatment duration not to exceed 2 consecutive weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Clinical Note
moderateClobetasol propionate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Gatifloxacin."
Clinical Note
moderateClobetasol propionate + Rosoxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Rosoxacin."
Clinical Note
moderateClobetasol propionate + Levofloxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is approximately 2-3 hours after topical application. However, due to prolonged cutaneous retention, clinical effects may persist beyond systemic elimination.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Primarily fecal (biliary) with minimal renal excretion. Less than 5% of a topical dose is recovered in urine as metabolites; the majority is eliminated via feces after hepatic metabolism.
Category C
Category A/B
Topical Corticosteroid
Topical Corticosteroid
Clobetasol propionate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Trovafloxacin."